{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:28:06Z","timestamp":1792744086617,"version":"4.5.0"},"reference-count":37,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Pathogenic variants of HNF1A cause maturity-onset diabetes of the young type 3 (HNF1A-MODY; also known as MODY3). Individuals with HNF1A-MODY are primarily treated with sulfonylureas; however, little is known about the effect of sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors in HNF1A-MODY. Interestingly, HNF1A-MODY is associated with increased glucosuria, which has been attributed to lower expression of SGLT2 as observed in HNF1A-knockout mice. We investigated the impact of acute SGLT2 inhibition on glucosuria in individuals with HNF1A-MODY or type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>In a randomized, double-blind, crossover study, individuals with HNF1A-MODY or type 2 diabetes underwent two three-step hyperglycemic clamps targeted at 1-h periods of 10, 14, and 18 mmol\/L glucose with and without acute SGLT2 inhibition (25 mg empagliflozin or placebo administrated 2 h before clamp procedures).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Eleven individuals with HNF1A-MODY (age [mean \u00b1 SD] 49 \u00b1 15 years; glomerular filtration rate [GFR; mean \u00b1 SD] 113 \u00b1 18 mL\/min) and 10 individuals with type 2 diabetes (age 63 \u00b1 7 years; GFR 103 \u00b1 27 mL\/min) were included. During the 3-h hyperglycemic clamp, SGLT2 inhibition increased urinary glucose excretion in both groups (HNF1A-MODY: 24.5 g [95% CI 20.6, 28.3]; type 2 diabetes: 23.5 g [95% CI 20.4, 26.5]). The effect of SGLT2 inhibition was not significantly different between the groups (1.0 g [95% CI \u22123.5, 5.6]; P = 0.6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The robust effect of SGLT2 inhibition on urinary glucose excretion in participants with HNF1A-MODY points to SGLT2 inhibition as a relevant glucose-lowering treatment strategy in individuals with HNF1A-MODY.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-0737","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:23:06Z","timestamp":1751541786000},"page":"1536-1544","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":8,"title":["Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-9898","authenticated-orcid":false,"given":"Henrik","family":"Maagensen","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne S.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine O.","family":"H\u00f8yerup","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.B.","family":"Thuesen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen 2 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Krogh","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"},{"name":"Clinic for Pituitary Disorders, Department of Medicine, Zealand University Hospital 3 , K\u00f8ge, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 4 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen 2 , Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, University of Copenhagen 5 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 4 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen 2 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 4 , Copenhagen, Denmark"},{"name":"Center for Clinical Metabolic Research, Copenhagen University Hospital\u2013Herlev and Gentofte 6 , Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"H\u00e6dersdal","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-6787","authenticated-orcid":false,"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital\u2013Steno Diabetes Center Copenhagen 1 , Herlev, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 4 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2026061714341012200_B1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/384455a0","article-title":"Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)","volume":"384","author":"Yamagata","year":"1996","journal-title":"Nature"},{"key":"2026061714341012200_B2","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/ijms23063222","article-title":"HNF1A mutations and beta cell dysfunction in diabetes","volume":"23","author":"Miyachi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026061714341012200_B3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00125-021-05631-z","article-title":"A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY","volume":"65","author":"Kettunen","year":"2022","journal-title":"Diabetologia"},{"key":"2026061714341012200_B4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001250050931","article-title":"Chronic diabetic complications in patients with MODY3 diabetes","volume":"41","author":"Isomaa","year":"1998","journal-title":"Diabetologia"},{"key":"2026061714341012200_B5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/diacare.19.9.915","article-title":"Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q","volume":"19","author":"Velho","year":"1996","journal-title":"Diabetes Care"},{"key":"2026061714341012200_B6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1464-5491.2009.02913.x","article-title":"Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene","volume":"27","author":"Steele","year":"2010","journal-title":"Diabet Med"},{"key":"2026061714341012200_B7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/dme.12992","article-title":"Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A\u2013MODY cohort","volume":"33","author":"Bacon","year":"2016","journal-title":"Diabet Med"},{"key":"2026061714341012200_B8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"key":"2026061714341012200_B9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc20-0408","article-title":"Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young yype 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA)","volume":"43","author":"Christensen","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061714341012200_B10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2337\/dc13-3007","article-title":"Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial","volume":"37","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes Care"},{"key":"2026061714341012200_B11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2026061714341012200_B12","doi-asserted-by":"crossref","first-page":"e40962","DOI":"10.1371\/journal.pone.0040962","article-title":"Metabolic profiling in maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers","volume":"7","author":"Gloyn","year":"2012","journal-title":"PLoS One"},{"key":"2026061714341012200_B13","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diacare.28.7.1751","article-title":"Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers","volume":"28","author":"Stride","year":"2005","journal-title":"Diabetes Care"},{"key":"2026061714341012200_B14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/embo-reports\/kvd071","article-title":"HNF1alpha controls renal glucose reabsorption in mouse and man","volume":"1","author":"Pontoglio","year":"2000","journal-title":"EMBO Rep"},{"key":"2026061714341012200_B15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.118.111807","article-title":"Nucleosome positioning and gene regulation of the SGLT2 gene in the renal proximal tubular epithelial cells","volume":"94","author":"Takesue","year":"2018","journal-title":"Mol Pharmacol"},{"key":"2026061714341012200_B16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2026061714341012200_B17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/(SICI)1096-9136(199810)15:10<816::AID-DIA714>3.0.CO;2-P","article-title":"A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1) gene","volume":"15","author":"Menzel","year":"1998","journal-title":"Diabet Med"},{"key":"2026061714341012200_B18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12020-017-1341-2","article-title":"A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus","volume":"57","author":"Hohendorff","year":"2017","journal-title":"Endocrine"},{"key":"2026061714341012200_B19","first-page":"21","article-title":"The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3","volume":"2021","author":"Sriravindrarajah","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026061714341012200_B20","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.diabet.2021.101248","article-title":"Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3","volume":"47","author":"Phan","year":"2021","journal-title":"Diabetes Metab"},{"key":"2026061714341012200_B21","doi-asserted-by":"crossref","first-page":"e15387","DOI":"10.1111\/dme.15387","article-title":"Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)","volume":"41","author":"Maagensen","year":"2024","journal-title":"Diabet Med"},{"key":"2026061714341012200_B22","unstructured":"World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation. Accessed 24 July 2023. Available from https:\/\/iris.who.int\/handle\/10665\/43588"},{"key":"2026061714341012200_B23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/17425255.2014.873788","article-title":"Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations","volume":"10","author":"Scheen","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026061714341012200_B24","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2337\/db20-0369","article-title":"The role of glucagon in the acute therapeutic effects of SGLT2 inhibition","volume":"69","author":"H\u00e6dersdal","year":"2020","journal-title":"Diabetes"},{"key":"2026061714341012200_B25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1042\/cs0660613","article-title":"Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man","volume":"66","author":"Rehling","year":"1984","journal-title":"Clin Sci (Lond)"},{"key":"2026061714341012200_B26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-13-0941","article-title":"Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans","volume":"170","author":"Bak","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026061714341012200_B27","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.3390\/ijms20215416","article-title":"Methods and guidelines for measurement of glucagon in plasma","volume":"20","author":"Holst","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026061714341012200_B28","unstructured":"Diabetes Trials Unit, University of Oxford\n          : HOMA calculator. Accessed 17 October 2024. Available from https:\/\/www.dtu.ox.ac.uk\/homacalculator"},{"key":"2026061714341012200_B29","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714341012200_B30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2026061714341012200_B31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2026061714341012200_B32","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3390\/ijerph18063166","article-title":"Variability of urinary creatinine in healthy individuals","volume":"18","author":"Sallsten","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026061714341012200_B33","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"2026061714341012200_B34","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2337\/db17-0100","article-title":"Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes","volume":"66","author":"Al-Jobori","year":"2017","journal-title":"Diabetes"},{"key":"2026061714341012200_B35","doi-asserted-by":"crossref","first-page":"e001178","DOI":"10.1136\/bmjdrc-2020-001178","article-title":"Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport","volume":"8","author":"Ferrannini","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061714341012200_B36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.kint.2016.01.027","article-title":"Tubular proteinuria in patients with HNF1\u03b1 mutations: HNF1\u03b1 drives endocytosis in the proximal tubule","volume":"89","author":"Terryn","year":"2016","journal-title":"Kidney Int"},{"key":"2026061714341012200_B37","doi-asserted-by":"crossref","first-page":"165898","DOI":"10.1016\/j.bbadis.2020.165898","article-title":"HNF1\u03b1 controls glucagon secretion in pancreatic \u03b1-cells through modulation of SGLT1","volume":"1866","author":"Sato","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1536\/835974\/dc250737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/9\/1536\/835974\/dc250737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:34:23Z","timestamp":1781721263000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/9\/1536\/162869\/Effect-of-SGLT2-Inhibition-on-Glucosuria-During-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-0737","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}